Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Advanced cutaneous squamous cell carcinoma, drawn from the whole corpus: 10 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Transplant recipients, who have the highest incidence, cannot safely receive the most effective drugs.
About half of patients do not respond to PD-1 blockade and there is no approved second-line therapy.
How much surgery and radiotherapy can be omitted after a complete neoadjuvant response is unsettled.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 17 changes by month →When this page itself was last checked or edited.
Cemiplimab for high-risk disease (C-POST, 2025).
Disease-free survival at 24 months 87.
A milestone in how this cancer is treated.
Metastatic or locally advanced cutaneous SCC not curable by surgery or radiation
No kidney rejection or graft loss in 12 kidney transplant recipients given cemiplimab after cross-taper to a mammalian target of rapamycin inhibitor with pulsed corticosteroids, with responses in 5 of 11 evaluable patients (46 per cent, 90 per cent confidence interval 22 to 73).